Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2696)

VOLUNTARY ANNOUNCEMENT

2024 FIRST QUARTERLY UPDATE

The board of directors (the "**Board**") of Shanghai Henlius Biotech, Inc. (the "**Company**", together with its subsidiaries collectively referred to as the "**Group**") provides a voluntary disclosure in respect of the Group's unaudited selected operational and financial information for the three months ended 31 March 2024 (the "**Reporting Period**").

In the first quarter of 2024, the Group capitalised on established first-entrant advantages, comprehensively promoted the commercialisation process of products, continuously built innovative business models and optimised resource allocation. During the Reporting Period, the Group realised an operating income of approximately RMB1,349 million. During the Reporting Period, the performance of two core products sold and promoted by the Group's in-house commercialisation team in mainland China (excluding Hong Kong, Macau and Taiwan regions, same as below) is set out below:

- HANQUYOU (trastuzumab for injection, European brand name: Zercepac®, proprietary name in the United States: HERCESSI™, "**HANQUYOU**"), was the first domestic trastuzumab approved for marketing independently developed by the Group, which also has been approved for marketing in Europe and the United States. With its differentiated advantages including flexible dose portfolio of 150mg and 60mg, free of preservatives, etc., HANQUOU has benefited over 180,000 Chinese patients since its marketing. During the Reporting Period, HANQUYOU recorded a sales revenue of approximately RMB671 million in mainland China.

- HANSIZHUANG (serplulimab injection, "**HANSIZHUANG**"), was the first self-developed bio-innovative drug of the Group approved for marketing and was also the first monoclonal antibody drug targeting PD-1 approved for first-line treatment of small cell lung cancer around the world. As of the date of the announcement, the indications of HANSIZHUANG approved for marketing in mainland China cover Microsatellite Instability-High solid tumours, squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC) and esophageal squamous cell carcinoma (ESCC), and the new drug application (NDA) for the fifth indication of non-squamous non-small cell lung cancer (NSCLC) has been accepted. During the Reporting Period, HANSIZHUANG recorded a sales revenue of approximately RMB334 million in mainland China.

Based on clinical needs, the Group will continue to devote itself to oncology, auto-immune diseases and other fields, and deepen global strategic layout, promote the high-quality product innovation, enhance market expansion and international cooperation so that we can further consolidate the commercial capability of Biopharma.

The financial information contained in this announcement is prepared based on the Group's internal management records and has not been audited or reviewed by external auditors and is therefore provided for investors' reference only. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 29 April 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and executive director, Mr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.